Biotech Values

[DewDiligence]

1Q23 worldwide Botox sales=$1.378, +1% QoQ*, +10%YoY:

https://news.abbvie.com/news/press-releases/abbvie-reports-first-quarter-2023-financial-results.htm

• US therapeutic: $587M (-4% QoQ, +18% YoY)
• US cosmetic: $409M (-3% QoQ*, -1% YoY)
--
US total: $996M (59% therapeutic; 41% cosmetic) was 72% of worldwide total


• Ex-US therapeutic: $132M (+16% QoQ, +24% YoY†)
• Ex-US cosmetic: $250M (+14 QoQ, +18% YoY†)
--
Ex-US total: $382M (35% therapeutic; 65% cosmetic) was 28% of worldwide total.


†Ex-US YoY growth measured in local currency, which eliminates the effect of fluctuating exchange rates.

*In the US market, botulinum-toxin sales for cosmetic indications are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.